RxDoctor Payments Data

Jonathan Prest, MD

Pulmonary Disease · Grand Rapids, MINPI 1730539511

Payments from drug & device makers

$7,124in general payments, 2019–2025

Across 32 payments — averaging $222.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • Inspire Medical Systems, Inc.$1K
  • Astellas Pharma US Inc$160
  • Idorsia Pharmaceuticals US Inc$58
  • AstraZeneca$46
  • GSK$28
  • plus $72 from 4 others

What the payments were for

  • Travel & lodging$3,73152%
  • Food & beverage$6759%
  • Education$2,71838%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,124 in reported general payments places this provider in the 70th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$31,028
Medicare patients
106
Services billed
341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol99$63,408
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$37,535
Spiriva RespimatTiotropium Bromide28$14,770
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$11,348
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$9,737
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate44$8,168
Advair HfaFluticasone Propion/Salmeterol13$4,287
BreynaBudesonide/Formoterol Fumarate11$2,402
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,204
Albuterol Sulfate HfaAlbuterol Sulfate70$1,850
Fluticasone Propionate60$614
Azelastine Hcl16$293
Prednisone36$165
Azithromycin13$155
Montelukast Sodium15$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$46$63,40899 claims
GSKTrelegy Ellipta, Anoro Ellipta$28$47,27267 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$17$26,11849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →